This article was originally published in The Tan Sheet
Center for Drug Evaluation & Research Director Stephen Galson announces he will appoint a new associate center director "to focus on broad drug safety policy and safety communication" as part of the planned reorganization of the center in a staff memo Nov. 4. The memo provides an update to the proposed CDER reorganization that Galson announced Oct. 19 in conjunction with the appointment of a new Office of Drug Safety head. "Consolidating certain drug safety-related activities to report to this new associate center director" was also suggested by Galson in the update. In addition to drug safety goals, Galson hopes CDER will embrace the Critical Path Initiative and "improve regulatory and drug development science." His suggestions include creating a new office that will report to the center director and "provide a locus in the center to catalyze Critical Path activities." In the memo, Galson announces the appointment of Paul Seligman, MD, to associate center director...
You may also be interested in...
Implementation of an FDA standard drug safety bulletin will be one area of focus for the agency's new Associate Director for Safety Policy & Communication Paul Seligman
“There’s a heightened need for products that deliver against health, hygiene and clean home concerns and a willingness to spend just a little bit more to ensure that I’m using a product that I know and trust,” says CFO Jon Moeller
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.